戊型病毒性肝炎研究进展  

Recent Progress in Hepatitis E

作　　者：夏宁邵[1] 张军[1] 李少伟[1] 葛胜祥[1] 吴婷[1] 郑子峥[1] 吴文翰[1] 史维国[1] 

机构地区：[1]厦门大学国家传染病诊断试剂与疫苗工程技术研究中心,福建厦门361005

出　　处：《厦门大学学报（自然科学版）》2011年第2期431-436,共6页Journal of Xiamen University：Natural Science

基　　金：国家高技术研究发展计划(863)重点项目(2006AA02A209);国家自然科学杰出青年基金(30925030);传染病重大专项(2009ZX10004-704);国家自然科学基金项目(30870514)

摘　　要：戊型病毒性肝炎是全球最主要的病毒性肝炎之一,近半个世纪多次发生大规模暴发,孕妇感染戊型肝炎后病死率高达20%.近年随着基于构象型表位多肽E2的戊型肝炎诊断试剂的出现,戊型肝炎的病原学诊断及流行病学调查均获得了较大的发展,越来越引起人们的重视.由我国自主创新研制的重组戊型肝炎疫苗现已在中国完成世界上首个Ⅲ期临床试验,其预防戊型肝炎的保护率达到100%（95%CI,72.1%~100.0%）.Hepatitis E is one of the most important viral hepatitis in the world.Lots of large scale hepatitis E outbreaks occurred in recent half century,in which the mortality rate is as high as 20% in pregnant women.With the successfully development of conformational polypeptide E2-based diagnostic reagents,clinical diagnosis and epidemiology study of hepatitis E progressed greatly.The recombinant hepatitis E vaccine developed by Chinese scientists has successfully finished phase III clinical trial in China,which is the first phase III clinical trial in the world,vaccine efficacy after 3 doses is 100%（95%CI,72.1% to 100.0%）.

关 键 词：戊型病毒性肝炎 戊型肝炎病毒 E2 诊断试剂 重组戊型肝炎疫苗 

分 类 号：R373.2[医药卫生—病原生物学]